Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.
Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.